在冠状动脉样硬化发展中通过定量性脂组学和蛋白质学方法来表征脂蛋白样本
Hiroaki Takeda1,2, Yoshihiro Izumi3, Yui Koike4
1Division of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
NPJ cardiovascular health
|March 3, 2026
概括
脂蛋白中的特定胺水平与冠状动脉样硬化进展相关. 这一发现为超越传统标记者对心血管疾病风险提供了新的见解.
科学领域:
- 心血管科学 心血管科学
- 脂质代谢 脂质代谢是什么
- 蛋白质组学和脂质组学
背景情况:
- 脂蛋白对脂质运输至关重要,其质量影响心血管健康.
- 目前的标记不充分预测心血管疾病风险.
- 容易患心肌梗塞的子提供了一个研究冠状动脉特异性动脉样硬化因素的模型.
研究的目的:
- 在冠状动脉样硬化进展期间描述脂蛋白组成.
- 为了识别冠状动脉样硬化的早期脂蛋白特异性标记物.
- 探索脂蛋白组成和疾病严重程度之间的关系.
主要方法:
- 量化脂质组学和蛋白质组学被用来对脂质蛋白和脂质蛋白中的 Apolipoproteins 进行分析.
- 在20个月的时间里,从子身上每四个月收集一次样本.
- 网络分析被用来将脂质与疾病严重程度联系起来.
主要成果:
- 冠状动脉样硬化症的严重程度与八个月的非常低密度和低密度脂蛋白中的长链和陶胺正相关.
- 这种关联独立于阿波利波蛋白和传统的脂质危险因素.
- 脂质类特定的群通过网络分析与疾病严重程度有关.
结论:
- 脂蛋白内特定胺的早期升高可能预测冠状动脉样硬化.
- 脂蛋白组成为心血管疾病风险提供了新的见解.
- 这种多学科的方法揭示了动脉样硬化发展的新贡献者.
相关概念视频
Lipid-derived Compounds in the Human Body
5.5K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
5.5K
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


